#12879 IRS-1 Inhibition Antibody Sampler Kit
|Phospho-IRS-1 (Ser302) (34C7) Rabbit mAb #2491||20 µl||WB||H, M||180||Rabbit IgG|
|Phospho-IRS-1 (Ser307) Antibody #2381||20 µl||WB||H, M, R||180||Rabbit|
|Phospho-IRS-1 (Ser318) (D51C3) Rabbit mAb #5610||20 µl||WB, IP||H, M||R||180||Rabbit IgG|
|Phospho-IRS-1 (Ser612) (C15H5) Rabbit mAb #3203||20 µl||WB||H, M, R||180||Rabbit IgG|
|Phospho-IRS-1 (Ser636/639) Antibody #2388||20 µl||WB||H, M, R||180||Rabbit|
|Phospho-IRS-1 (Ser1101) Antibody #2385||20 µl||WB, IP||H, M, R||180||Rabbit|
|IRS-1 (D23G12) Rabbit mAb #3407||20 µl||WB, IP||H, M, R, Mk||180||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
†Species predicted to react based on 100% sequence homology.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Reactivity Key: H=Human, M=Mouse, R=Rat, Mk=Monkey
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of IRS-1 (#2382) antibody-immunoprecipitated pellets from differentiated C2C12 cells, unstimulated, insulin-stimulated (100 nM for 15 min) or PMA-stimulated (200 mM for 30 min), using Phospho-IRS-1 (Ser1101) Antibody (upper) or IRS-1 Antibody #2382 (lower).
Western blot analysis of insulin treated (100 nM, 5 min) MCF7 and C2C12 cells using Phospho-IRS-1 (Ser302) (34C7) Rabbit mAb.
Western blot analysis of MCF-7 cell extracts, unstimulated and insulin-stimulated (100 nM for 5 min), using IRS-1 Antibody #2382 (left) and Phospho-IRS-1 (Ser307) Antibody (right).
Western blot analysis of cell extracts from CHO IR/IRS-1 cells, untreated or treated with insulin, using Phospho-IRS-1 (Ser612) (C15H5) Rabbit mAb (upper and middle) or IRS-1 Antibody #2382 (lower). The middle blot was treated with calf intestinal phosphatase (CIP) before antibody probing.
Western blot analysis of MCF7, C2C12 and RD cell lines using IRS-1 (D23G12) Rabbit mAb.
Western blot analysis of extracts from serum-starved C2C12 cells, untreated or insulin-treated (150 nM for 5 min.), using Phospho-IRS-1 (Ser318) (D51C3) Rabbit mAb (upper), or IRS-1 Antibody #3407 (lower).
Western blot analysis of extracts from C2C12 cells, untreated or insulin-treated (100 nM, 5 min) using, Phospho-IRS-1 (Ser636/639) Antibody.
Western blot analysis of extracts from CHO IR/IRS-1 cells (transfected with insulin receptor and IRS-1), untreated or insulin-treated (100 nM for 5 min), showing an increase in phospho-IRS-1 (Ser307) with insulin stimulation, using Phospho-IRS-1 (Ser307) Antibody.
Insulin receptor substrate 1 (IRS-1) is one of the major substrates of the insulin receptor kinase (1). IRS-1 contains multiple tyrosine phosphorylation motifs that serve as docking sites for SH2-domain containing proteins that mediate the metabolic and growth-promoting functions of insulin (2-4). IRS-1 also contains over 30 potential serine/threonine phosphorylation sites, many of which are related to negative feedback loops activated during insulin signaling. Ser302 (human Ser307) of IRS-1 is regulated by FOX01 (5), IKKγ, and MYO1C (6). Ser307 (human Ser312) of IRS-1 is phosphorylated by JNK (7) and IKK (8). PKC phosphorylates mouse IRS-1 at Ser318 (human Ser323) by insulin receptor activation or by other stimulation such as TPA, IL-6, and retinoic acid treatment (9-12). The PKC and mTOR pathways mediate phosphorylation of IRS-1 at Ser612 (human Ser616) and Ser632/635 (human Ser636/639), respectively (13,14). Phosphorylation of IRS-1 at Ser1097 (human Ser1101) is mediated by PKCθ and results in an inhibition of insulin signaling in the cell, suggesting a potential mechanism for insulin resistance in some models of obesity (15).
- Sun, X.J. et al. (1991) Nature 352, 73-7.
- Sun, X.J. et al. (1992) J Biol Chem 267, 22662-72.
- Myers, M.G. et al. (1993) Endocrinology 132, 1421-30.
- Wang, L.M. et al. (1993) Science 261, 1591-4.
- Cao, Y. et al. (2006) J Biol Chem 281, 40242-51.
- Nakamori, Y. et al. (2006) J Cell Biol 173, 665-71.
- Rui, L. et al. (2001) J Clin Invest 107, 181-9.
- Gao, Z. et al. (2002) J Biol Chem 277, 48115-21.
- Greene, M.W. et al. (2004) Biochem J 378, 105-16.
- Weigert, C. et al. (2006) J Biol Chem 281, 7060-7.
- del Rincón, S.V. et al. (2004) Oncogene 23, 9269-79.
- Moeschel, K. et al. (2004) J Biol Chem 279, 25157-63.
- Ozes, O.N. et al. (2001) Proc Natl Acad Sci U S A 98, 4640-5.
- De Fea, K. and Roth, R.A. (1997) Biochemistry 36, 12939-47.
- Li, Y. et al. (2004) J Biol Chem 279, 45304-7.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.